Formycon AG (0W4N.L)
EUR 53.2
(0.95%)
EUR 53.2
(0.95%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 387.61 Million EUR | -22.03% |
| 2022 | 497.11 Million EUR | 3253.46% |
| 2021 | 14.82 Million EUR | 96.0% |
| 2020 | 7.56 Million EUR | 41.51% |
| 2019 | 5.34 Million EUR | -16.28% |
| 2018 | 6.38 Million EUR | 20.82% |
| 2017 | 5.28 Million EUR | 23.03% |
| 2016 | 4.29 Million EUR | 88.68% |
| 2015 | 2.27 Million EUR | -30.28% |
| 2014 | 3.26 Million EUR | 2.22% |
| 2013 | 3.19 Million EUR | -5.48% |
| 2012 | 3.37 Million EUR | 639.5% |
| 2011 | 457 Thousand EUR | 118.4% |
| 2010 | 209.25 Thousand EUR | 243.03% |
| 2009 | 61 Thousand EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 371.47 Million EUR | 0.0% |
| 2023 Q2 | 485.52 Million EUR | 0.0% |
| 2023 FY | 387.61 Million EUR | -22.03% |
| 2023 Q4 | 387.61 Million EUR | 0.0% |
| 2022 Q2 | 424.96 Million EUR | 0.0% |
| 2022 FY | 497.11 Million EUR | 3253.46% |
| 2022 Q4 | 497.11 Million EUR | 0.0% |
| 2021 FY | 14.82 Million EUR | 96.0% |
| 2021 Q4 | 10.26 Million EUR | 0.0% |
| 2021 Q2 | 12.13 Million EUR | 0.0% |
| 2020 FY | 7.56 Million EUR | 41.51% |
| 2020 Q4 | 7.56 Million EUR | 0.0% |
| 2020 Q2 | 5.35 Million EUR | 0.0% |
| 2019 FY | 5.34 Million EUR | -16.28% |
| 2019 Q4 | 5.34 Million EUR | 0.0% |
| 2019 Q2 | 4.19 Million EUR | 0.0% |
| 2018 FY | 6.38 Million EUR | 20.82% |
| 2018 Q2 | 9.07 Million EUR | 0.0% |
| 2018 Q4 | 6.38 Million EUR | 0.0% |
| 2017 Q4 | 5.28 Million EUR | 0.0% |
| 2017 FY | 5.28 Million EUR | 23.03% |
| 2017 Q2 | 3.26 Million EUR | 0.0% |
| 2016 FY | 4.29 Million EUR | 88.68% |
| 2016 Q4 | 4.29 Million EUR | 0.0% |
| 2016 Q2 | 1.73 Million EUR | 0.0% |
| 2015 Q4 | 2.27 Million EUR | 0.0% |
| 2015 FY | 2.27 Million EUR | -30.28% |
| 2015 Q2 | 2.93 Million EUR | 0.0% |
| 2014 Q2 | 448.75 Thousand EUR | 0.0% |
| 2014 FY | 3.26 Million EUR | 2.22% |
| 2014 Q4 | 3.26 Million EUR | 0.0% |
| 2013 Q4 | 3.19 Million EUR | 0.0% |
| 2013 FY | 3.19 Million EUR | -5.48% |
| 2013 Q2 | 2.89 Million EUR | 0.0% |
| 2012 Q4 | 3.37 Million EUR | 0.0% |
| 2012 Q2 | 5.36 Million EUR | 0.0% |
| 2012 FY | 3.37 Million EUR | 639.5% |
| 2011 FY | 457 Thousand EUR | 118.4% |
| 2010 FY | 209.25 Thousand EUR | 243.03% |
| 2009 FY | 61 Thousand EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Boiron SA | 198.7 Million EUR | -95.072% |
| Laboratorios Farmaceuticos Rovi, S.A. | 256.39 Million EUR | -51.18% |
| Vetoquinol SA | 165.12 Million EUR | -134.742% |
| Valneva SE | 341.14 Million EUR | -13.621% |
| AB Science S.A. | 46.5 Million EUR | -733.429% |
| Nanobiotix S.A. | 95.74 Million EUR | -304.858% |
| PHAXIAM Therapeutics S.A. | 25.69 Million EUR | -1408.507% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | -8424.544% |
| BioSenic S.A. | 32.26 Million EUR | -1101.373% |
| ABIVAX Société Anonyme | 131.05 Million EUR | -195.769% |